Spots Global Cancer Trial Database for ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Official Title: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
Study ID: NCT05653271
Study Description
Brief Summary: ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
AdventHealth Orlando, Orlando, Florida, United States
Emory University, Atlanta, Georgia, United States
Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Norton Cancer Institute, Louisville, Kentucky, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Tamsui MacKay Memorial Hospital, New Taipei City, , Taiwan
Linkou Chang-Gung Memorial Hospital, Taoyuan City, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
